The Executive Leadership Team and organizational structure for the combined company of Novozymes and Chr. Hansen is announced. The new setup is designed to secure the future company's ambition to become a global leading biosolutions partner.

The market-driven structure facilitates a strengthened innovation and commercial focus, it creates simplicity, enhances the customer experience, and ignites even stronger growth for the company. The new organizational structure will take effect on day one of the combined company, which is expected to be no later than in the fourth quarter of 2023 or in the first quarter of 2024, subject to regulatory approval. The current members of the Executive Leadership Team of Novozymes and the Corporate Leadership Team of Chr.

Hansen will continue in their roles until day one of the combined company. The following nine Executives have been appointed to the future Executive Leadership Team. Additionally, following strong focus on the integration process, the General Counsel will report directly to the CEO until no later than by the end of 2024 when the area will revert to the CFO responsibilities.

Ester Baiget, CEO, Rainer Lehmann, CFO, Jacob Paulsen, EVP, Food & Beverage Biosolutions, Amy Byrick, EVP, Human Health Biosolutions, Tina Sejersgaard Fanoe, EVP, Planetary Health Biosolutions, Claus Crone Fuglsang, Chief Scientific Officer, Anders Lund, Chief Operating Officer, Henrik Joerck Nielsen, EVP, Strategy & Integration, Morten Enggaard Rasmussen, EVP, People & Stakeholder Relations and Winnie Bügel, General Counsel - Legal.